Oncotelic Announces Peer-Reviewed Validation of Deciparticle(TM) Platform Supporting Clinical Development of Sapu003

Stock Information for Autolus Therapeutics plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Autolus Therapeutics plc

Oncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6th
OTCQB Virtual Investor Conference Agenda Announced for August 5 & 6
Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle(TM) Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus)
Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway
Oncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026
Oncotelic Advances AI-Powered GMP Manufacturing Services Platform for Revenue-Generating AI and Robotics Manufacturing Services
Oncotelic Showcases PDAOAI(TM) Capability in Advancing Drug Development. Featured in Qdrant Vector Space Day 2026 Keynote
NetworkNewsAudio Announces Audio Press Release (APR) Discussing the Exploration of Nanoparticle, Targeted Drug-Delivery Technologies

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.